Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07283640 | A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | PHASE1 | NOT YET_RECRUITING | 20 | — | — | May 18, 2026 | Aug 31, 2031 | May 5, 2026 | 1 | United States |
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Treatment with SC Blinatumomab + Revumenib in R/R ALL |
| Cohort 2 | EXPERIMENTAL | Treatment with SC Blinatumomab + Revumenib in Newly Diagnosed ALL |
| Name | Type | Description |
|---|---|---|
| Revumenib | DRUG | Given by po |
| Blinatumomab | DRUG | Given by IV |
Eligibility Criteria • The following groups of participants will be eligible: * Participants \> 18 years of age with relapsed and/or refractory (defined as \>5% blasts in the peripheral blood or bone marrow) KMT2A-r B-cell ALL or * Participants \>18 years of age with persistent measurable residual...